A new Cambridge-based orphan drug accelerator launched today with $16 million in financing led by New Enterprise Associates and Pfizer Venture Investments.

Cydan LLC will focus on identifying promising assets with well-understood biology and proof-of-concept data for in vivo models from academia, industry and other sources, officials said.

Data generated from a de-risking process will enable Cydan to form stand-alone companies and strategic partnerships, officials said. Additionally, Cydan will evaluate a wide range of drug platforms and technologies.

The article you requested has been archived

All coverage within bostonherald.com from the last 14 days remains free of charge. Articles do not always include original photos, charts or graphics.